

Robotic Antimicrobial Susceptibility Platform (RASP): a next-generation approach to One Health surveillance of antimicrobial resistance

Alec Truswell¹†, Rebecca Abraham¹†, Mark O’Dea¹, Zheng Zhou Lee¹, Terence Lee¹, Tanya Laird¹, John Blinco¹,
Shai Kaplan², John Turnidge³, Darren J. Trott³, David Jordan^{1,4}‡ and Sam Abraham¹*‡

¹Antimicrobial Resistance and Infectious Diseases Laboratory, College of Science, Health, Engineering and Education, Murdoch University, Murdoch, Australia; ²SciRobotics Ltd, Kefar Sava, Israel; ³Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, SA, Australia; ⁴New South Wales Department of Primary Industries, Wollongbar, NSW, Australia

*Corresponding author. E-mail: s.abraham@murdoch.edu.au

†These authors contributed equally.

‡These authors jointly supervised this work.

Received 22 January 2021; accepted 5 March 2021

Background: Surveillance of antimicrobial resistance (AMR) is critical to reducing its wide-reaching impact. Its reliance on sample size invites solutions to longstanding constraints regarding scalability. A robotic platform (RASP) was developed for high-throughput AMR surveillance in accordance with internationally recognized standards (CLSI and ISO 20776-1:2019) and validated through a series of experiments.

Methods: Experiment A compared RASP’s ability to achieve consistent MICs with that of a human technician across eight replicates for four *Escherichia coli* isolates. Experiment B assessed RASP’s agreement with human-performed MICs across 91 *E. coli* isolates with a diverse range of AMR profiles. Additionally, to demonstrate its real-world applicability, the RASP workflow was then applied to five faecal samples where a minimum of 47 *E. coli* per animal (239 total) were evaluated using an AMR indexing framework.

Results: For each drug–rater–isolate combination in Experiment A, there was a clear consensus of the MIC and deviation from the consensus remained within one doubling dilution (the exception being gentamicin at two dilutions). Experiment B revealed a concordance correlation coefficient of 0.9670 (95% CI: 0.9670–0.9670) between the robot- and human-performed MICs. RASP’s application to the five faecal samples highlighted the intra-animal diversity of gut commensal *E. coli*, identifying between five and nine unique isolate AMR phenotypes per sample.

Conclusions: While adhering to internationally accepted guidelines, RASP was superior in throughput, cost and data resolution when compared with an experienced human technician. Integration of robotics platforms in the microbiology laboratory is a necessary advancement for future One Health AMR endeavours.

Introduction

Antimicrobial resistance (AMR) has been described as one of the greatest threats to global health and food security, with an estimated cumulative cost of 100 trillion USD by 2050.¹ The major consequence of resistance is the escalating difficulty of successfully treating bacterial infections with the currently available limited array of antimicrobials. We now face the risk of returning to the pre-antibiotic era where bacterial infections in humans and

animals were a major cause of mortality.² Preserving the usefulness of existing antimicrobials by reducing selection and limiting the dissemination of resistant organisms is therefore a high priority. Consequently, a key component of management efforts is surveillance designed to keep authorities and clinicians aware of where and when resistance is present and evolving.³ Surveillance of AMR faces many challenges owing to the multi-host, multi-pathogen, multi-drug nature of the resistance phenomenon.

Perhaps one of the most problematic aspects is the insidious nature of resistance—it emerges slowly without necessarily yielding expression of any outward signs and frequently has an impact at a place and time other than its origin. For surveillance to overcome these obstacles, careful attention needs to be paid to the choice of pairing of assays for measuring resistance in bacteria and the design of sample acquisition from animals, food and the environment.

Surveillance for AMR in animals and food is a well-established activity. The WHO has longstanding recommendations for the conduct of ‘integrated surveillance’, as part of the multifaceted management for the control of resistance.⁴ Countries such as Denmark⁵ and the USA⁶ have been at the forefront of surveillance for AMR in animals and the food chain with programmes running since as early as 1995. Since then, the basic approach in food animals, which is now widely adopted throughout the developed world, has changed very little. A core component is the collection and analysis of data relating to the AMR profile of indicator bacteria (such as *Escherichia coli*) from various livestock and commodities.⁷ As a result of the high cost per isolate (of which laboratory processing contributes a significant portion), most national-level surveys typically only collect data on approximately 150–250 individually selected isolates per year from each livestock sector. While the resulting data provide a general overview on AMR in food animals, the inferences that can be drawn are limited. In addition, recent data have demonstrated variation of *E. coli* resistance profiles within bacterial species from the same host,⁸ suggesting that reliable estimates of AMR require the collection of multiple isolates from a single host.

In order to effectively limit the emergence and spread of AMR within groupings of animals or humans, surveillance data must be strengthened to make it more relevant to antimicrobial stewardship.⁹ A paramount need is for the individuals responsible for antimicrobial stewardship in a setting to receive intelligence from surveillance describing the occurrence of resistance. To deliver such feedback, epidemiologically appropriate study design and sample size needs to be combined with cost-effective characterization of much larger numbers of bacteria than are currently evaluated.¹⁰ At present, the isolation of large numbers of bacterial colonies, subsequent antimicrobial susceptibility testing (AST) with traditional techniques and genomic characterization is not only cost prohibitive but a severe drain on time and resources. Scaling up traditional methods is unattractive because it would inevitably introduce inaccuracy arising from fatigue of laboratory workers. However, the harnessing of high-throughput laboratory robotic platforms capable of handling individual colonies on an unprecedented scale and without the loss of accuracy from fatigue we associate with manual methods is a practical solution.

In this study, we describe the development of the next-generation approach to surveillance for AMR using a Robotic Antimicrobial Susceptibility Platform (RASP) and demonstrate that the RASP method is elegantly and efficiently adapted to high-volume surveillance of commensal organisms. The system automates the process of bacterial isolation, identification (with or without reliance on spectrography) and AST for customized combinations of drugs. With this comes a much-needed improvement in the ability to design surveillance to meet objectives that are of practical relevance at the coalface of antimicrobial stewardship.

Methods

System overview

RASP was developed to assess phenotypic resistance in a manner comparable with major surveillance programmes. Unlike other approaches to ‘scaling up’ such as metagenomics, RASP keeps the nucleic acid of individual isolates available for study, making it possible to understand if resistance is mediated by previously unidentified genes while avoiding biases due to the presence of extraneous nucleic acid from environmental organisms.

RASP is a customizable robotics platform that was designed, using available Tecan (Switzerland) and SciRobotics Ltd (Israel) products, to be flexible and multifunctional, capable of bacterial isolation, isolate collection, preparation for identification and AST. A Tecan Freedom EVO[®] 150 base was combined with the SciRobotics carousel capable of holding both Petri dishes and 96-well microplates. SciRobotics equipment was incorporated into the robot deck, the PetriPlater[™] to dispense samples and Pickolo[™] software using image analysis to select colonies, in addition to a microplate absorbance reader for AST inoculum adjustment to deliver high-throughput surveillance (Figure S1, available as [Supplementary data](#) at JAC Online). The robot has also been fully integrated with barcoding capabilities to track isolates from original source to phenotypic results and is integrable with any electronic laboratory information management system. The general workflow for this method is visualized in Figure 1 and the major steps detailed below. Homogenized samples are loaded onto the robot in a liquid format and either serially diluted or directly streaked onto agar. After incubation individual colonies are selected using Pickolo[™], based on the explicit requirements of the user, including colour, size and morphology. Individual colonies are transferred to a 96-well microplate and a deep-well plate in preparation for AST and isolate storage, respectively. MALDI-TOF identification can also be performed at this timepoint and, as such, the robot includes a position for a MALDI-TOF target plate and is capable of both sample and matrix addition. AST is then performed using an entirely liquid-based methodology adapted for the RASP platform from internationally established guidelines: CLSI¹¹ and ISO 20776-1:2019; including compliance to quality control criteria. AST drug panels, genotyping and WGS can be prepared using the Freedom EVO genomics platform. While the above workflow was well suited to this current study, it should be noted that it represents one of many possibilities. RASP workflows are flexible and, due to the modular design of hardware, can be adjusted to suit different bacterial species, sample types, culture media and drug panels.

Bacterial isolation

Two grams of faecal sample was homogenized in 18 mL PBS. Homogenized samples then underwent four 10-fold serial dilutions and were plated onto CHROMagar[™] ECC (Edwards, MM1076) using the two-zone spiral plating protocol at 10⁻³ (outer zone) and 10⁻⁴ (inner zone) (Video S1). After overnight incubation at 37°C, Pickolo[™] colony picking software was used to target and pick up to 48 presumptive *E. coli* colonies per plate based on their adherence to previously determined colour, size and circularity criteria (Video S2) and transferred to 96-well plates containing CAMHB (BD, 212322) for overnight growth at 37°C for storage and subsequent assays.

Bacterial identification

Isolates were prepared for MALDI-TOF identification by adding 40 µL of 90% formic acid to the bacterial pellet from overnight culture (Video S3). Species identification was then performed by MALDI-TOF adhering to manufacturer’s protocol (Bruker MALDI Biotyper Microflex LT/SH MALDI-MS running MBT Compass 4.1 Build 70 and flexControl 3.4 Build 135).




Figure 1. Overview of a typical RASP workflow. Any processes depicted outside the border occur externally to RASP. This figure appears in colour in the online version of *JAC* and in black and white in the print version of *JAC*.

AST

All isolates were grown from storage at -80°C onto sheep blood agar (Edwards, MM1120) overnight at 37°C . A second subculture was performed the following day, and the workflow diverged depending on the prospective rater.

RASP platform

Isolates intended for robot-performed susceptibility testing were subcultured in a flat-bottom 96-well plate (Nunc, 167008), each well filled with $220\ \mu\text{L}$ (allowing for overnight evaporation of roughly $20\ \mu\text{L}$) CAMHB (BD, 212322). The robot protocol adjusted isolates from the overnight broth culture using an absorbance reader at $620\ \text{nm}$ wavelength to an absorbance equivalent to a McFarland standard (0.08 to 0.13). The McFarland standardized isolate was transferred to a deep-well plate and diluted 1:20 in sterile water, and the drug plate was inoculated with $10\ \mu\text{L}$ of isolate in $90\ \mu\text{L}$ of CAMHB-diluted drug (Video S4). For colony enumeration, the robot performed further dilutions (1:150 followed by another 1:150) on the previously diluted McFarland standard and plated $100\ \mu\text{L}$ on sheep blood agar using a modification of the two-zone spiral dilution plating method; whereby the

entire plate is inoculated as just one zone (lawn plating). Following an overnight incubation (16–20 h at 37°C as per CLSI guidelines), drug plate results for both raters were read using the Sensititre Vizion plate reader system, and colony enumeration on sheep blood agar was performed and recorded using the Pickolo™ colony counting software.

Human technician

Isolates intended for human-performed susceptibility testing were subcultured on sheep blood agar. The human broth microdilution protocol followed CLSI guidelines, with the adjustment of isolates to a 0.5 McFarland standard using a nephelometer (Sensititre™), followed by a 1:100 dilution in CAMHB prior to inoculation of the drug plate using Sensititre's AIM™ automated inoculation delivery system ($50\ \mu\text{L}$ inoculum into $50\ \mu\text{L}$ of drug diluted in CAMHB). The colony enumeration quality control step was performed for each isolate on sheep blood agar as per CLSI guidelines with a 1:1000 dilution of inoculum in 0.9% saline and lawn plating on agar.

Validation and application of RASP

To evaluate the capacity of the robot and validate its use in AST, we applied the RASP robotic platform to the aforementioned workflow using a collection of *E. coli* because *E. coli* is an ideal indicator organism and represents a ubiquitous component of surveillance for AMR in animals.^{5,6,12}

AST validation Experiment A: assessment of repeatability

An experiment was conducted to validate the RASP platform's AST protocol by comparing the ability of both human and robot rater to generate consistent MICs across replicates. Each rater performed AST on four *E. coli* isolates in octuplicate against the following antimicrobials: ampicillin, cefoxitin, ceftiofur, chloramphenicol, ciprofloxacin, colistin, ceftriaxone, florfenicol, gentamicin, streptomycin, trimethoprim/sulfamethoxazole, and tetracycline. Isolates were derived from various sources including an American Type Culture Collection 25922, and one isolate of seagull,¹³ porcine¹⁴ and cattle origin,¹⁵ each with previously determined AMR profiles.

AST validation Experiment B: assessment of rater agreement

Experiment B was a breadth study whereby the RASP platform and an experienced human technician performed AST on a diverse range of isolates ($n=91$) with varying, previously characterized AMR profiles and host origins (seagull, porcine, cattle).^{13–17} The RASP platform was assessed based on its agreement with the human technician in their determination of MICs for each isolate. Antimicrobials tested included: ampicillin, cefoxitin, ceftiofur, chloramphenicol, ciprofloxacin, colistin, ceftriaxone, florfenicol, gentamicin, streptomycin, trimethoprim/sulfamethoxazole, and tetracycline.

RASP workflow application: antimicrobial resistance surveillance index scoring

To demonstrate the level of resolution achievable with RASP, five faecal samples were collected from pig pen floors (one sample per pen) and proceeded through the RASP workflow described above to yield AST data for 239 derivative *E. coli* isolates (minimum to 47 per sample) against six antimicrobials (ampicillin, ceftiofur, ciprofloxacin, gentamicin, tetracycline and trimethoprim/sulfamethoxazole). A secondary classification and visualization script devised in Stata¹⁸ was applied to the 239 isolates to generate a graphical representation of intra-animal and intra-herd diversity, as well as to assign an index score representative of the threat posed by their

AMR burden. The indexing scheme assigned weights (w) to antimicrobials informed by national¹⁹ and international²⁰ guidelines whereby the antimicrobials deemed more important to human health received a higher weighting. Antimicrobial weights were as follows: ampicillin ($w = 1$), ceftiofur ($w = 3$), ciprofloxacin ($w = 4$), gentamicin ($w = 2$), tetracycline ($w = 1$), and trimethoprim/sulfamethoxazole ($w = 2$). In this study, the maximum possible AMR score was 13, indicating resistance to all tested antimicrobials.

Throughput comparison analysis

An analytical component of this study sought to compare the time required by a human technician utilizing current methods, versus a robot-assisted technician, to process 20 homogenized faecal samples (deriving 960 isolates) from isolation through to phenotypic characterization. A simulated workflow was developed for each technician based on average times taken to perform each task within the workflow and

applied to the above scenario. The human technician was allowed the use of 'modern' laboratory implements such as Sensititre's auto-inoculator and Vizion plate reader systems, pre-ordered ready-to-use drug plates and a MALDI-TOF, while the robot-assisted technician had the two previously discussed Tecan robots, a MALDI-TOF and a Sensititre Vizion plate reader system at their disposal.

Results

AST validation Experiment A: assessment of repeatability

In Experiment A, when comparing the human (H) and robot (R) MIC results for each isolate, the mode MIC for an isolate across both raters against a specific antimicrobial was labelled the 'consensus MIC' and any deviation from the consensus MIC deemed a




Figure 2. Experiment A: comparison of human ('H') and robot ('R') MIC results for four fully susceptible *E. coli* isolates each replicated eight times per rater, tested against a panel of antimicrobials. Each isolate-rater designation displays the MIC results for all eight replicates of that combination. Antimicrobials: AMP, ampicillin; CIP, ciprofloxacin; GEN, gentamicin; TET, tetracycline. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.




Figure 3. Experiment B: paired MIC results on 96 isolates with 12 drugs directly comparing human and robot measurements. Marker size represents proportion of paired observations for the isolate–drug combination. Antimicrobials: AMP, ampicillin; FOX, ceftiofur; CFT, ceftiofur; CHL, chloramphenicol; CIP, ciprofloxacin; CST, colistin; CRO, ceftriaxone; FLO, florfenicol; GEN, gentamicin; STR, streptomycin; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.

departure from the truest result (Figure 2). Of the drug–rater–antimicrobial combinations tested (see Figure S2 for all combinations), the majority showed all eight replicates having achieved the same MIC result, and furthermore demonstrate agreement between the two raters; all isolates and replicates tested against tetracycline achieved the same MIC between both isolate and rater. Of the cases where deviation from the consensus MIC was seen, it was limited to one doubling dilution (the exception being gentamicin at two dilutions) and there remained moderate agreement between the two raters, with similar distributions of replicates across MIC results.

AST validation Experiment B: assessment of rater agreement

In Experiment B, the majority of combinations of isolates and drugs (67.6%) tested showed complete agreement between the two human and robot raters while 23.4% had a discrepancy in MIC result by one, which is acceptable according to international guidelines, and 9.0% had a discrepancy of two or more doubling dilutions (Figure 3). The greatest discrepancy in MIC between raters

was a difference of nine dilutions between the two results and represented 0.26% of the isolate–drug combinations tested. The overall agreement for isolate–drug combinations between robot and human was summarized by a concordance correlation coefficient of 0.9670 (95% CI: 0.9670–0.9670), $N = 1092$.

RASP workflow application: antimicrobial resistance surveillance index scoring

All homogenized faecal samples that were plated by RASP on CHROMagar™ ECC selective agars yielded growth of at least 48 single colonies matching the expected blue appearance of *E. coli* at one or both dilutions. Isolates were successfully identified as *E. coli* using RASP's MALDI-TOF preparation protocol, all with high identification scores; the lowest identification score achieved was 2.2, which qualified within Bruker's highest confidence range.

Samples from all animals exhibited a diverse range of AMR profiles amongst isolates, including resistance to antimicrobials tested (Figure 4). All animals, except one, had isolates representing an AMR index of zero. The highest AMR index recorded was 13, comprising resistance to all tested antimicrobials. A relatively balanced




Figure 4. Antimicrobial resistance indexing scheme applied to 239 porcine *E. coli* isolates (48 from pigs A, B C and E and 47 from pig D) using the following antimicrobial risk weightings (w): ampicillin ($w = 1$), ceftiofur ($w = 3$), ciprofloxacin ($w = 4$), gentamicin ($w = 2$), tetracycline ($w = 1$) and trimethoprim/sulfamethoxazole ($w = 2$). Colours are representative of the highest weighted resistance present for an isolate. This figure appears in colour in the online version of *JAC* and in black and white in the print version of *JAC*.

distribution of AMR indices was seen for the 48 isolates from most animals; the exception being pig ‘E’, from which isolates were heavily skewed towards low AMR indices, with a high density achieving an AMR index of one.

Throughput comparison analysis

It was estimated that the human technician would take 30 days to process these samples compared with 9 days for a robot-assisted technician (Figure S3). It is important to state that the robots were not in continuous use during this workflow, meaning there was time where they could also have been utilized for other tasks.

Discussion

The impetus to transition microbiology from a manual-labour-centric profession to one embracing automation is nothing novel. Automation offers the same advantage it has provided industry for decades; the augmentation of processes to increase efficiency and throughput; and this statement holds true for the application of the RASP platform to a conventional microbiology workflow. Typically, several technicians would be required in the manual

workflow depicted in Figure S3 to prevent the occurrence of issues such as fatigue, and even still it is unlikely that optimal pace and quality of work would be maintained for the entirety of the workflow; a problem to which the robot is immune. The utilization of robotics instead allows staff to be diverted from monotonous and error-prone tasks to more cognitively intensive ones such as data analysis and project management.^{21,22} These increases to throughput are only significant, however, if the solution is financially viable. It is therefore important to note that the improvement in processing efficiency is just one of several ways by which automation alleviates sample-processing costs; savings are also seen on materials and reagents as a result of the transition to liquid-based methodologies (90% estimated cost reduction). In consideration of the initial financial outlay of purchasing the RASP platform (400 000 AUD; equivalent to approximately 300 000 USD or 260 000 EUR), we determined that approximately 9000 samples would need to be processed for the above savings to equate to this initial cost. The incorporation of robotics into the routine microbiological assays described in this study is the technological leap required to elevate the standard of future One Health AMR surveillance.

While currently available laboratory robotic systems (e.g. VITEK[®], Microscan, WASPLab[®] and BD Phoenix[™]) do offer the automation of isolation, identification or AST, in comparison with RASP they utilize largely inflexible (in terms of pre-determined AST panels and characterization of a single isolate)²³ procedures to generate this information. To our knowledge, we have developed the first integrated system—from isolation to AMR profile production that meets international guidelines and demonstrated that the method meets or exceeds the standards required. The Freedom EVO microbiology robot and by association the RASP protocol described here utilize broth microdilution testing and MALDI-TOF integration (both gold-standard microbiological procedures) to capitalize on the higher throughput and resolution of data offered by its liquid-adapted methods.

AST completed by the robot was comparable to human-generated data with similar patterns of MIC variance observed. AST in its current format is highly variable as can be seen by the wide range of MIC values acceptable for highly tested ATCC control strains.¹¹ This phenomenon was well depicted in Experiment A, where under well-controlled, faithfully replicated conditions, MIC results from replicates of the same isolate spanning two or three doubling dilutions were commonly observed. The symmetry of MIC distributions between raters in these instances suggests that the source of this variation is biological in nature, due perhaps to phenomena such as isolates expelling their plasmid, delayed expression of AMR genes or natural assay variations, as opposed to a technical failure by either rater.

Due to the restrictions of conventional methods considered above, most surveys will collect information for approximately 200 isolates per year per country, which limits the inferences that can be drawn. For example, with respect to the ability to detect early emergence of resistance to a key drug, a simple application of binomial probability (expressed as: $P(X > 0) | X \sim \text{Bin}(200, 0.0001)$) demonstrates that a survey relying on 200 isolates has a probability of only 1.98% of detecting any positives if only 0.01% of isolates in the population have the resistance trait of interest. This calculation substantially underestimates the true number of isolates required during surveillance because reliance on a multi-staged sampling design (selection of herds, then animals, then isolates) is essential and carries a cost in accuracy created by the design effect.²⁴ The AMR indexing experiment included in this study supports other data^{8,25} in confirming that variation of *E. coli* resistance profiles within bacterial species from the same host and same group of animals is commonplace. The high level of resolution available from RASP for describing resistance in microbial populations, and its ability to yield an affordable increase in the number of samples and isolates assessed, was demonstrated in the final validation experiment in this study by the diversity of AMR profiles. In this final study only 0.4% ($n = 1$) of tested isolates had an AMR index of 13, 1.7% ($n = 4$) had resistance to gentamicin and 1.3% ($n = 3$) had resistance to ceftiofur. There was also a corresponding variation in the number of AMR profiles for *E. coli* within a host: there being from 6–9 distinct variants detected in individuals, and more would likely be detected with higher sample sizes. With the availability of RASP there is an unprecedented opportunity to strengthen the management of AMR by shifting from a focus of interpretation adapted to clinical isolates to one that expressly accommodates the diversity of resistance in hosts at every level of organization. Data generated on an expanded scale by RASP

therefore presents an opportunity to provide more meaningful guidance on antimicrobial stewardship at the farm level through to national and international policy.

Conclusions

RASP and technologies alike unlock a higher calibre of AMR surveillance by overcoming longstanding constraints to scalability. The flexibility of RASP permits its application well beyond the scope demonstrated here, to the diverse range of bacterial landscapes encountered in the One Health system. This study saw RASP's workflow benchmarked against that of a contemporary laboratory, where it was demonstrated to be equivalent to an experienced human technician but proved superior in throughput, endurance and cost. It is critical that microbiology harnesses robotic platforms like RASP if we are to resist the current trajectory of AMR.

Funding

This project was supported by funding from the Australian Government Department of Agriculture, Water and the Environment as part of its Rural R&D for Profit programme.

Transparency declarations

S.K. is the co-owner, co-CEO and head of R&D at SciRobotics Ltd. All other authors: none to declare.

Author contributions

A.T., R.A., Z.Z.L., T. Laird and S.A. designed and performed the plating and colony picking experiments. A.T., R.A., J.B. and S.A. designed and performed the antimicrobial susceptibility testing experiments. J.T. and D.J.T. provided consultation on the antimicrobial susceptibility testing experiments as well as assisting with its validation according to international guidelines. S.K. developed the RASP platform adapting the hardware and software for microbiological use and provided consultation throughout the study. S.A., D.J., R.A., M.O. and D.J.T. conceived the project and S.A., R.A., M.O. and D.J. supervised the project. A.T., R.A., D.J., T. Lee and S.A. performed data analysis. A.T., R.A., D.J. and S.A. wrote the initial draft of the manuscript, T. Lee, A.T., R.A. and S.A. designed figures and all authors contributed to editing and proofreading of the manuscript.

Supplementary data

Figures [S1](#) to [S3](#) and Videos [S1](#) to [S4](#) are available as [Supplementary data](#) at JAC Online.

References

- 1 O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. HM Government and Wellcome Trust: UK 2016. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf.
- 2 WHO. Antimicrobial resistance: global report on surveillance, 2014. <https://www.who.int/antimicrobial-resistance/publications/surveillance-report/en/>.
- 3 WHO. Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2017–2018. 2018. <https://www.who.int/glass/resources/publications/early-implementation-report-2017-2018/en/>.

- 4** WHO. Integrated Surveillance of Antimicrobial Resistance in Foodborne Bacteria: Application of a One Health Approach. 2017. Licence: CC BY-NC-SA 3.0 IGO. <https://apps.who.int/iris/handle/10665/255747>.
- 5** DANMAP. Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. ISSN 1600-2032. 2018. https://backend.orbit.dtu.dk/ws/files/210256829/DANMAP_2018_1_.pdf.
- 6** FDA. 2016-2017 NARMS Integrated Summary. Rockville, MD: U.S. Department of Health and Human Services. <https://www.fda.gov/animal-veterinary/national-antimicrobial-resistance-monitoring-system/2016-2017-narms-integrated-summary-interactive>.
- 7** Schrijver R, Stijntjes M, Rodriguez-Baño J *et al.* Review of antimicrobial resistance surveillance programmes in livestock and meat in EU with focus on humans. *Clin Microbiol Infect* 2018; **24**: 577–90.
- 8** Tenailon O, Skurnik D, Picard B *et al.* The population genetics of commensal *Escherichia coli*. *Nat Rev Microbiol* 2010; **8**: 207–17.
- 9** Tacconelli E, Sifakis F, Harbarth S *et al.* Surveillance for control of antimicrobial resistance. *Lancet Infect Dis* 2018; **18**: e99–e106.
- 10** McArthur AG, Tsang KK. Antimicrobial resistance surveillance in the genomic age. *Ann NY Acad Sci* 2017; **1388**: 78–91.
- 11** CLSI. *Performance Standards for Antimicrobial Susceptibility Testing—Twenty-Ninth Edition: M100*. 2019.
- 12** Abraham S, O’Dea M, Sahibzada S *et al.* *Escherichia coli* and *Salmonella spp.* isolated from Australian meat chickens remain susceptible to critically important antimicrobial agents. *PLoS One* 2019; **14**: e0224281.
- 13** Mukerji S, Stegger M, Truswell AV *et al.* Resistance to critically important antimicrobials in Australian silver gulls (*Chroicocephalus novaehollandiae*) and evidence of anthropogenic origins. *J Antimicrob Chemother* 2019; **74**: 2566–74.
- 14** Abraham S, Kirkwood RN, Laird T *et al.* Dissemination and persistence of extended-spectrum cephalosporin-resistance encoding Inc11-blaCTXM-1 plasmid among *Escherichia coli* in pigs. *ISME J* 2018; **12**: 2352–62.
- 15** Barlow RS, McMillan KE, Duffy LL *et al.* Prevalence and antimicrobial resistance of *Salmonella* and *Escherichia coli* from Australian cattle populations at slaughter. *J Food Prot* 2015; **78**: 912–20.
- 16** Abraham S, Jordan D, Wong HS *et al.* First detection of extended-spectrum cephalosporin- and fluoroquinolone-resistant *Escherichia coli* in Australian food-producing animals. *J Glob Antimicrob Resist* 2015; **3**: 273–7.
- 17** Mukerji S, Gunasekera S, Dunlop JN *et al.* Implications of foraging and interspecies interactions of birds for carriage of *Escherichia coli* strains resistant to critically important antimicrobials. *Appl Environ Microbiol* 2020; **86**: 20.
- 18** StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp.
- 19** Jordan D. Antimicrobial ratings: the importance of importance. *Aust Vet J* 2019; **97**: 283–4.
- 20** WHO. Critically important antimicrobials for human medicine, 6th revision. 2019. Licence: CC BY-NC-SA 3.0 IGO. <https://apps.who.int/iris/bitstream/handle/10665/312266/9789241515528-eng.pdf>.
- 21** Bailey AL, Ledebore N, Burnham C-AD. Clinical microbiology is growing up: the total laboratory automation revolution. *Clin Chem* 2019; **65**: 634–43.
- 22** Evans JV. Automation and molecular diagnostics: a new era in clinical microbiology. *Clin Lab Sci* 2020; doi:10.29074/ascls.119.001883.
- 23** Snyder JW, Thomson GK, Heckman S *et al.* Automated preparation for identification and antimicrobial susceptibility testing: evaluation of a research use only prototype, the BD Kiestra IdentifA/SusceptA system. *Clin Microbiol Infect* 2020; doi:10.1016/j.cmi.2020.07.007.
- 24** Bell BA, Onwuegbuzie AJ, Ferron JM *et al.* Use of design effects and sample weights in complex health survey data: a review of published articles using data from 3 commonly used adolescent health surveys. *Am J Public Health* 2012; **102**: 1399–405.
- 25** Dunlop R, McEwen S, Meek A *et al.* Sampling considerations for herd-level measurement of faecal *Escherichia coli* antimicrobial resistance in finisher pigs. *Epidemiol Infect* 1999; **122**: 485–96.